BioTissue Technologies AG
BioTissue AG english
BioTissue Technologies AG with new board member
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
BioTissue Technologies AG with new board member
Freiburg, February 25Th, 2002 – BioTissue Technologies AG (SIN 618061) hereby
announces that Dr. Wilhelm Brandner, CEO and in charge of Marketing and Sales,
will be retiring from the Company on mutual agreement as of Feb. 28, 2002.
As of March 1, 2002 Dr. Victor Tiegermann (48) will be taking over the function
of CEO and assuming responsibility for Marketing and Sales. Dr. Tiegermann
previously held various leading management positions with a sales thrust in
medical companies active in orthopedics and dermatology, in both Europe and the
United States. His main tasks at Sulzer Medica, Stryker Biotech and most
recently Modex Therapeutics included marketing innovative and complex medical
products and technologies.
BioTissue Technologies AG, Martin Braendle, Investor Relations Manager
Tel.: +49-761-7676110, Fax: +49-761-7676155
martin.braendle@biotissue-tec.com
end of ad-hoc-announcement (c)DGAP 25.02.2002
Issuer’s information/explanatory remarks concerning this ad-hoc-announcement:
Freiburg, February 25Th, 2002 – BioTissue Technologies AG (SIN 618061) hereby
announces that Dr. Wilhelm Brandner, CEO and in charge of Marketing and Sales,
will be retiring from the Company on mutual agreement as of Feb. 28, 2002.
As of March 1, 2002 Dr. Victor Tiegermann (48) will be taking over the function
of CEO and assuming responsibility for Marketing and Sales. Dr. Tiegermann
previously held various leading management positions with a sales thrust in
medical companies active in orthopedics and dermatology, in both Europe and the
United States.
His main tasks included in each case marketing innovative and complex medical
products and technologies.
Dr. Tiegermann studied natural sciences at the Federal Institute of Technology
(ETH) in Zurich and was awarded a Ph.D. in biomechanics.
At Sulzer Medica, he acted as Vice President Marketing and Sales; in that
capacity he was responsible for the world-wide launch and marketing of new types
of hip and knee prostheses.
As Director International Product Development at Stryker Biotech he likewise
worked in the field of orthopedics; he was in charge of the introduction and
marketing of the bone growth factor rhOP-1.
Most recently, Dr. Tiegermann was Director Tissue Engineering at Modex
Therapeutics, where he had overall responsibility for Epidex, the autologous
skin substitute.
“Tissue Engineering enters now the adolescent age. I am convinced that at
BioTissue, this phase will become a success story”, explains Tiegermann.
BioTissue Technologies will continue to focus on the especially lucrative
orthopedics market and will thus be able to benefit from Dr. Tiegermann’s
international experience in this field.
BioTissue Technologies AG, Martin Braendle, Investor Relations Manager
Tel.: +49-761-7676110, Fax: +49-761-7676155
martin.braendle@biotissue-tec.com
——————————————————————————–
WKN: 618061; ISIN: DE0006180615; Index:
Listed: Neuer Markt in Frankfurt;
Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und
Stuttgart
250827 Feb 02
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden